Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Qilu Hospital of Shandong University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06735326CT.gov Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT06161272CT.gov Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | — | Unknown | — | — | — |
NCT06063070CT.gov First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT04229615CT.gov A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluzoparib (this asset) | Qilu Hospital of Shandong University | P3 | B · 56 |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Carboplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BB |
| Epirubicin | OncoC4, Inc. | P3 | BB |
| Metformin | University of Chicago | P2 | BB |
+42 more in the Fallopian Tube Cancer cohort
Other indications for Fluzoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P3 | B · 62 |
| Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluzoparib in Fallopian Tube Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluzoparib-fallopian-tube-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →